Pfizer gifts the NHS with breast cancer drug

Breaking News

Brexit – Implications For the Pharma Industry in Ireland The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,...
EMA to Work With Stakeholders to Improve Product Information For EU Medicines The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in...
Diaceutics Wins at Export Industry Awards Diaceutics, the Irish data insights and solutions company helping patients receive potentially lifesaving medicine through better testing, won the Small & Emerging Exporter of the Year Award at the recent Export...
Brexit – Key Issues For the Pharmaceutical Industry Brexit – the stark reality is that the UK’s EU membership and the application of all EU legislation in the UK ends automatically at midnight on 30th March 2019! Current understanding...
European Commission Diagnoses the State of Health in the EU Only by rethinking our health systems can we ensure that they remain fit-for-purpose and provide patient-centred care. This is what the 28 Country Health Profiles recently published by the Commission,...

Pfizer gifts the NHS with breast cancer drug

May 10

11:16 2017

Print This Article Share it With Friends

Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the NHS for free for up to five months until a final decision by NICE is made.

It is estimated that around 6,000 patients across the UK would be eligible for this therapy each year. In comparison with other treatments it has been demonstrated to prolong the patient’s life by 10 months.

“This is an unexpected lifeline for thousands of women living with this type of breast cancer,” said Fiona Hazell, director of policy and engagement at the charity Breast Cancer Now. “Palbociclib can offer a large proportion of patients with incurable metastatic breast cancer significant extra time before their disease progresses — time that can be truly invaluable to them and their loved ones.”

Furthermore, Pfizer has clarified that for those patients receiving the treatment for free during this interim period, if it is rejected for NHS use, they will not be taken off it and will not have to start paying.

Written by Felicity Thomas

About Author

Scroll Back To Top More Articles From Author

colin

Scroll Back To Top

Biopharma Business